Sensei Biotherapeutics：Piktor治疗晚期子宫内膜癌的II期关键数据预计2026年下半年公布_老虎社区_美港股上老虎

Sensei Biotherapeutics：Piktor治疗晚期子宫内膜癌的II期关键数据预计2026年下半年公布

美股速递06-15

Sensei Biotherapeutics公司宣布，其候选药物Piktor针对晚期子宫内膜癌的II期临床试验关键性数据，预计将于2026年下半年公布。这一时间表为关注该疗法进展的投资者和医学界提供了明确的时间节点。

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

暂无评论

热议股票

7x24

全部

{"i18n":{"language":"zh_CN"},"data":{"share":"https://www.laohu8.com/m/news/1197135575?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2026-06-15 20:12","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1197135575","market":"us","top_or_hot":-1,"title":"Sensei Biotherapeutics：Piktor治疗晚期子宫内膜癌的II期关键数据预计2026年下半年公布","media":"美股速递","content":"<p>Sensei Biotherapeutics公司宣布，其候选药物Piktor针对晚期子宫内膜癌的II期临床试验关键性数据，预计将于2026年下半年公布。这一时间表为关注该疗法进展的投资者和医学界提供了明确的时间节点。</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Sensei Biotherapeutics：Piktor治疗晚期子宫内膜癌的II期关键数据预计2026年下半年公布</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nSensei Biotherapeutics：Piktor治疗晚期子宫内膜癌的II期关键数据预计2026年下半年公布\n</h2>\n\n<h4 class=\"meta\">\n\n2026-06-15 20:12 北京时间&nbsp;&nbsp;&nbsp;<strong>美股速递</strong>\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Sensei Biotherapeutics公司宣布，其候选药物Piktor针对晚期子宫内膜癌的II期临床试验关键性数据，预计将于2026年下半年公布。这一时间表为关注该疗法进展的投资者和医学界提供了明确的时间节点。</p>\n\n<a href=\"\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"FTH","symbol_name":"Faeth Therapeutics","start_time":0,"source_url":"","article_id":"1197135575","we_media_id":"1004306016","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1197135575","pubTimestamp":1781525543,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"美股速递","introduction":"全球快讯第一时间播报","home_visible":1,"id":"1004306016","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"Sensei Biotherapeutics公司宣布，其候选药物Piktor针对晚期子宫内膜癌的II期临床试验关键性数据，预计将于2026年下半年公布。这一时间表为关注该疗法进展的投资者和医学界提供了明确的时间节点。","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"zh","relate_stocks":{"FTH":"Faeth Therapeutics","SNSE":"Sensei Biotherapeutics, Inc.","BK4139":"生物科技"},"translate_title":"Sensei Biotherapeutics: Piktor's Phase II Key Data for Advanced Endometrial Cancer Expected in the Second Half of 2026","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"FTH":1,"SNSE":1},"content_text":"Sensei Biotherapeutics公司宣布，其候选药物Piktor针对晚期子宫内膜癌的II期临床试验关键性数据，预计将于2026年下半年公布。这一时间表为关注该疗法进展的投资者和医学界提供了明确的时间节点。","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":true,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"hasMoreComments":false,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"isCrawlerRequest":true}